Key facts
- It has raised $107.1M across 1 recorded rounds; the latest was Early Stage VC ($27.1M) in Mar 2024.
- Notable investors include Alumni Ventures, Andreessen Horowitz, Mana Ventures, Khosla Ventures, Gaingels — 22 tracked in total.
- Q Bio has filed 1 Form D with the SEC, most recently Jul 2024 ($27.1M sold to 14 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for Q Bio
Funding rounds
1 roundsAbout Q Bio
Operator of a clinical digital twin platform designed to assess the medical history of patients in order to flag their immediate and future health risks. The company's platform performs whole-body scans to generate a digital twin of the patient's physical body to quantify and digitize, the data and utilize simulated human physiology and machine learning to predict potential health risks, enabling healthcare personnel to render proactive treatment to patients.
- Sector
- Healthcare
- HQ
- San Carlos, CA, United States
- Founded
- 2015
- Employees
- 34
- Website
- q.bio/
- Ownership
- Privately Held (backing)
Q Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Q Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Q Bio in its N-PORT filings yet. We sweep new filings monthly.